Goldie Locks

Goldilocks Therapeutics is a biopharmaceutical company specializing in the development of kidney-directed therapies through a proprietary prodrug platform. The company's technology is designed to selectively deliver therapeutic agents to the renal proximal tubule, maximizing local efficacy while minimizing systemic toxicity. Their lead program, GT-001, is a renal-targeted glucocorticoid being developed for the treatment of acute kidney injury (AKI). By concentrating drug activity within the kidney, Goldilocks aims to address significant unmet needs in nephrology and improve outcomes for patients with renal diseases. The company's approach leverages specific renal transporters to ensure precise drug delivery, embodying a Goldilocks principle of achieving the optimal therapeutic balance.